Based on the Werewolf Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Werewolf Therapeutics Inc is USD 6.00 over the next 12 months. Werewolf Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Werewolf Therapeutics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Werewolf Therapeutics Inc’s stock price was USD 0.70. Werewolf Therapeutics Inc’s stock price has changed by -32.20% over the past week, -43.69% over the past month and -88.20% over the last year.
No recent analyst target price found for Werewolf Therapeutics Inc
No recent average analyst rating found for Werewolf Therapeutics Inc
Company Overview Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Read Less
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive ...Read More
Frequently Asked Questions About Werewolf Therapeutics Inc (HOWL) Stock
Based on ratings from 2 analysts Werewolf Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on HOWL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for HOWL is USD 6.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 4.
HOWL stock's Price/Earning ratio is 0.66.
Our analysis grades HOWL stock's Price / Earning ratio at C. This means that HOWL stock's Price/Earning ratio is above 26% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HOWL may be undervalued for its sector.
The last closing price of HOWL's stock was USD 0.70.
The most recent market capitalization for HOWL is USD 0.06B.
Based on targets from 2 analysts, the average taret price for HOWL is projected at USD 6.00 over the next 12 months.
This means that HOWL's stock price may go up by +759.23% over the next 12 months.
We can't find any ETFs which contains Werewolf Therapeutics Inc's stock.
As per our most recent records Werewolf Therapeutics Inc has 45 Employees.
Werewolf Therapeutics Inc's registered address is 200 Talcott Ave, Watertown, MA, United States, 02472.
You can get more information about it from Werewolf Therapeutics Inc's website at https://werewolftx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Werewolf Therapeutics Inc (HOWL) Stock
Based on ratings from 2 analysts Werewolf Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on HOWL's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for HOWL is USD 6.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 4.
HOWL stock's Price/Earning ratio is 0.66.
Our analysis grades HOWL stock's Price / Earning ratio at C. This means that HOWL stock's Price/Earning ratio is above 26% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HOWL may be undervalued for its sector.
The last closing price of HOWL's stock was USD 0.70.
The most recent market capitalization for HOWL is USD 0.06B.
Based on targets from 2 analysts, the average taret price for HOWL is projected at USD 6.00 over the next 12 months.
This means that HOWL's stock price may go up by +759.23% over the next 12 months.
We can't find any ETFs which contains Werewolf Therapeutics Inc's stock.
As per our most recent records Werewolf Therapeutics Inc has 45 Employees.
Werewolf Therapeutics Inc's registered address is 200 Talcott Ave, Watertown, MA, United States, 02472.
You can get more information about it from Werewolf Therapeutics Inc's website at https://werewolftx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HOWL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
